GeneTether Therapeutics Inc
CNSX:GTTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GeneTether Therapeutics Inc
CNSX:GTTX
|
CA |
|
W
|
Waja Company SCJSC
SAU:9560
|
SA |
|
M
|
Masaru Corp
TSE:1795
|
JP |
|
V
|
Virtuix Holdings Inc
NASDAQ:VTIX
|
US |
GeneTether Therapeutics Inc
GeneTether Therapeutics, Inc. is an innovative medicines company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2022-03-28. The firm is focused on the development of high-efficiency precision gene editing for human therapeutics applications. The firm is engaged in creating gene editing therapies based on its GeneTether platform. The company is engaged in building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. Its GeneTether platform also allows for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases. Its GeneTether platform has the potential to significantly improve upon current gene editing methods by actively positioning reparative DNA fragments, which are referred to as donor DNA templates. By positioning a donor DNA template directly at the site of a double strand break, the GeneTether platform drives the DNA repair process towards homology-directed repair (HDR).
GeneTether Therapeutics, Inc. is an innovative medicines company. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2022-03-28. The firm is focused on the development of high-efficiency precision gene editing for human therapeutics applications. The firm is engaged in creating gene editing therapies based on its GeneTether platform. The company is engaged in building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. Its GeneTether platform also allows for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases. Its GeneTether platform has the potential to significantly improve upon current gene editing methods by actively positioning reparative DNA fragments, which are referred to as donor DNA templates. By positioning a donor DNA template directly at the site of a double strand break, the GeneTether platform drives the DNA repair process towards homology-directed repair (HDR).
